Trial results

Liraglutide (Saxenda(R)) in Adolescents With Obesity After Sleeve Gastrectomy

NCT04883346 on ClinicalTrials.gov · last registry update 2024-11-20

A small phase 2 — 34 participants, against a typical 110. The sponsor logged completion for 15 March 2024. Primary outcome, as filed: Cohen's d (the Standardized Mean Difference). liraglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status

COMPLETED

Phase

P2

Drug

liraglutide

Saxenda, Victoza, Xultophy

Sponsor

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Sponsor type

Nih

Enrollment

34

Started

2021-06-21

Primary completion

2024-03-15 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Cohen's d (the Standardized Mean Difference)

Conditions studied

Obesity · Status Post Sleeve Gastrectomy

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.